AU759743B2 - Lysozyme fusion proteins in infections - Google Patents

Lysozyme fusion proteins in infections Download PDF

Info

Publication number
AU759743B2
AU759743B2 AU23459/00A AU2345900A AU759743B2 AU 759743 B2 AU759743 B2 AU 759743B2 AU 23459/00 A AU23459/00 A AU 23459/00A AU 2345900 A AU2345900 A AU 2345900A AU 759743 B2 AU759743 B2 AU 759743B2
Authority
AU
Australia
Prior art keywords
fusion protein
lysozyme
seq
mammal
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU23459/00A
Other languages
English (en)
Other versions
AU2345900A (en
Inventor
Henry Toyin Akinbi
Timothy Edward Weaver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cincinnati Childrens Hospital Medical Center
Original Assignee
Cincinnati Childrens Hospital Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/193,877 external-priority patent/US5993809A/en
Application filed by Cincinnati Childrens Hospital Medical Center filed Critical Cincinnati Childrens Hospital Medical Center
Publication of AU2345900A publication Critical patent/AU2345900A/en
Application granted granted Critical
Publication of AU759743B2 publication Critical patent/AU759743B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462Lysozyme (3.2.1.17)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU23459/00A 1998-11-18 1999-11-18 Lysozyme fusion proteins in infections Ceased AU759743B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/193,877 US5993809A (en) 1998-11-18 1998-11-18 Lysozyme fusion proteins in infections
US09/193877 1998-11-18
US44074299A 1999-11-16 1999-11-16
US09/440742 1999-11-16
PCT/US1999/027403 WO2000029588A1 (fr) 1998-11-18 1999-11-18 Traitement d'infections au moyen de proteines de fusion lysozyme

Publications (2)

Publication Number Publication Date
AU2345900A AU2345900A (en) 2000-06-05
AU759743B2 true AU759743B2 (en) 2003-05-01

Family

ID=26889453

Family Applications (1)

Application Number Title Priority Date Filing Date
AU23459/00A Ceased AU759743B2 (en) 1998-11-18 1999-11-18 Lysozyme fusion proteins in infections

Country Status (6)

Country Link
EP (1) EP1129201A1 (fr)
JP (1) JP2002530083A (fr)
AU (1) AU759743B2 (fr)
BR (1) BR9915218A (fr)
CA (1) CA2349837A1 (fr)
WO (1) WO2000029588A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1194570A1 (fr) 1999-06-23 2002-04-10 PPL Therapeutics (Scotland) Limited Proteines de fusion incorporant un lysozyme
DE60331601D1 (de) * 2003-12-18 2010-04-15 Univ Giessen Justus Liebig Neue chimärische plasminogenaktivatoren und deren pharmazeutische verwendung
WO2005108563A2 (fr) * 2004-04-19 2005-11-17 University Of Chicago Proteine hydrolysant le peptidoglycane encodée par bacteriophage n4
JP2008528032A (ja) * 2005-01-27 2008-07-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 原発性嚢胞性線維症欠陥を標的化する薬剤の効力を性質決定するための方法
EP2697387B1 (fr) * 2011-04-12 2021-09-15 Bactoclear Holdings PTE. LTD. Polypeptides chimères antibactériens
CN104817618B (zh) * 2014-01-30 2018-07-03 陈光健 寡肽cd01及其制备方法和应用
CN104817616A (zh) * 2014-01-30 2015-08-05 陈光健 寡肽cd02及其制备方法和应用
CN114149986B (zh) * 2022-02-08 2022-05-06 中国科学院天津工业生物技术研究所 一种地衣芽孢杆菌溶菌酶突变体及其在虹鳟鱼保鲜中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3540075A1 (de) * 1985-11-12 1987-05-14 Boehringer Ingelheim Int Human-lysozym
DE3818094C1 (fr) * 1988-05-27 1989-07-20 Medichemie Ag, Ettingen, Ch
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances

Also Published As

Publication number Publication date
AU2345900A (en) 2000-06-05
EP1129201A1 (fr) 2001-09-05
JP2002530083A (ja) 2002-09-17
BR9915218A (pt) 2001-07-31
CA2349837A1 (fr) 2000-05-25
WO2000029588A1 (fr) 2000-05-25

Similar Documents

Publication Publication Date Title
US5993809A (en) Lysozyme fusion proteins in infections
CA2181164C (fr) Procede et matieres de traitment d'infections bacteriennes a gram positif
US5948408A (en) DNA encoding bactericidal/permeability-increasing proteins
EP1659132A1 (fr) Fragments de BPI
Moss Cystic fibrosis: pathogenesis, pulmonary infection, and treatment
WO2003045976A2 (fr) Utilisation de proteines et peptides antimicrobiens dans le traitement de l'otite moyenne et de la sinusite paranasale
JP2002544759A (ja) カチオン性ペプチド単独、または抗生物質と組み合わせて用いて感染を処置するための組成物および方法
US7985729B2 (en) Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
EP2030980A1 (fr) Mutants de lactoferrine
AU759743B2 (en) Lysozyme fusion proteins in infections
US5939279A (en) Inhibition of bacterial binding by high-mannose oligosaccharides
US5043156A (en) Method of treating infectious diseases with granulocyte colony-stimulating factor
US20060194732A1 (en) Recombinant SP-A for the treatment or prevention of pulmonary infection and inflammation
US6767538B2 (en) Recombinant antibacterial group IIA phospholipase A2 and methods of use thereof
JP7423523B2 (ja) ディフェンシンによる移植片対宿主病の予防と治療
CZ308296A3 (en) Use of heparin-bonding protein for treating sepses, process of its preparation and pharmaceutical composition containing thereof
JP6713148B2 (ja) 腹膜炎の治療のための組成物
US5770561A (en) Method for potentiating BPI protein product bactericidal activity by administration of LBP protein products
US6132775A (en) Therapeutic uses of biologically active bactericidal/permeability-increasing protein fragments
US20090088364A1 (en) Pharmaceutical composition useful for the treatment of invasive pulmonary aspergillosis
KR20210148320A (ko) 사람 혈청의 존재하에 슈도모나스 아에루기노사에 대해 살균 활성을 갖는 리신 및 이의 유도체
Sakurai et al. Effect of Macrolide Antibiotics on Biological Activities Induced by Clostridium perfringens Alpha-Toxin
Rae The effect of Mannheimia haemolytica pneumonia on antimicrobial peptide expression in ruminant lung

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)